Evidence map›Paper›PMID 40883594›Full record

ArticleCommunications medicine2025

Harnessing an integrated glyco-nanovaccine technology for enhanced cancer immunotherapy.

Mayumi Niimura, Yasuhisa Sakamoto, Mayuko Shimoda, Narumi Harada, Ayato Maeda, Shiho Wada, Koki Murata, Chanida Thinyakul, Saisai Liu, Haruka Ohara and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Mayumi NiimuraDepartment of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Yasuhisa Sakamoto *Department of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Mayuko Shimoda *Department of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Narumi HaradaDepartment of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID http://orcid.org/0000-0002-4100-0184
Ayato MaedaDepartment of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID http://orcid.org/0009-0009-7232-7831
Shiho WadaDepartment of Engineering, Chemistry and Biotechnology program, Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
Koki MurataDepartment of Engineering, Chemistry and Biotechnology program, Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
Chanida ThinyakulDepartment of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Saisai LiuDepartment of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Haruka OharaDepartment of Engineering, Chemistry and Biotechnology program, Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
Asuka IwamotoDepartment of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Yohei KanamoriDepartment of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Akihiro NitaDivision of Cellular Dynamics, Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo, Tokyo, Japan.
Masahiro WakaoDepartment of Engineering, Chemistry and Biotechnology program, Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
Yasuo SudaCollaborative Research Laboratory on Glyco-nanotechnology, Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
Hiroyuki OshiumiDepartment of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID http://orcid.org/0000-0003-1567-8722
Tomoko HayashiDivision of Rheumatology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Dennis A CarsonDivision of Rheumatology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Hiroyuki ShinchiDepartment of Engineering, Chemistry and Biotechnology program, Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan. hshinchi@eng.kagoshima-u.ac.jp.ORCID http://orcid.org/0000-0001-5204-9170
Toshiro MoroishiDepartment of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. moroishi.toshiro@tmd.ac.jp.ORCID http://orcid.org/0000-0001-6419-3882

Funding

Japan Agency for Medical Research and Development (AMED) JP22cm0106382, JP22gm6210030MEXT | Japan Science and Technology Agency (JST) JPMJPR17HA, JPMJFR226JMEXT | Japan Society for the Promotion of Science (JSPS) 24H00864, 24H00865
6 · The paper itself

Abstract

backgroundCancer immunotherapy, particularly using immune checkpoint inhibitors, has revolutionized cancer treatment; however, its efficacy remains limited to a subset of patients. Nanoparticles have potential in cancer treatment because they offer advantages such as biocompatibility, greater stability, and precise targeting capabilities.

methodWe synthesized an integrated glyco-nanovaccine (iGN) comprising gold nanoparticles conjugated with a synthetic Toll-like receptor 7 (TLR7) ligand, sugar chains, and peptide antigens for cancer immunotherapy. The potential of iGN was investigated using a therapeutic animal model.

resultsIn murine models, iGN effectively induces antigen-specific cytotoxic T cells, demonstrating prophylactic and therapeutic efficacy against tumor growth. iGN stimulates antigen-presenting cells via the TLR7-MYD88 pathway, enhancing antigen presentation and priming of cytotoxic T cells. Combination therapy with iGN and anti-PD-1 antibodies improves survival of tumor-bearing mice.

conclusionsThese findings underscore the potential of iGN as a strategy to enhance cancer immunotherapy, particularly when used in combination with immune checkpoint blockade, to bolster anti-tumor immune responses and improve therapeutic outcomes.

Identifiers

PMID40883594
PMCPMC12397435

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.